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Liver fibrosis is a reversible wound-healing response
involving TGFb1/SMAD activation of hepatic stellate
cells (HSCs). It results from excessive deposition of
extracellular matrix components and can lead to
impairment of liver function. Here, we show that
vitamin D receptor (VDR) ligands inhibit HSC activa-
tion by TGFb1 and abrogate liver fibrosis, whereas
Vdr knockout mice spontaneously develop hepatic
fibrosis. Mechanistically, we show that TGFb1
signaling causes a redistribution of genome-wide
VDR-binding sites (VDR cistrome) in HSCs and facil-
itates VDRbinding at SMAD3profibrotic target genes
via TGFb1-dependent chromatin remodeling. In the
presence of VDR ligands, VDR binding to the coregu-
lated genes reduces SMAD3 occupancy at these
sites, inhibiting fibrosis. These results reveal an inter-
secting VDR/SMAD genomic circuit that regulates
hepatic fibrogenesis and define a role for VDR as
an endocrine checkpoint to modulate the wound-
healing response in liver. Furthermore, the findings
suggest VDR ligands as a potential therapy for liver
fibrosis.
INTRODUCTION
Hepatic fibrosis, defined by excessive accumulation of extracel-
lular matrix (ECM) and resultant loss of pliability and liver func-
tion, is the result of wound-healing responses triggered by either
acute or chronic liver injury (Bataller and Brenner, 2005; Hernan-
dez-Gea and Friedman, 2011; Lee and Friedman, 2011). The
main causes of liver injury leading to fibrosis in industrialized
countries include chronic hepatitis virus (hepatitis B virus/hepa-
titis C virus) infection, alcohol abuse, and, increasingly, nonalco-holic steatohepatitis (Friedman, 1999, 2003; Friedman and
Bansal, 2006; Siegmund et al., 2005). With persistent injury,
there is progressive deposition of fibrillar collagens, eventually
leading to parenchymal nodules surrounded by collagen bands,
the histological signature of hepatic cirrhosis (Bataller and Bren-
ner, 2005; Friedman, 2003).
Chronic liver disease and cirrhosis represent a major global
health concern (Bataller and Brenner, 2005). In Australia and
the United Kingdom, chronic liver disease is the fifth most com-
mon cause of death, after heart disease, cancer, stroke, and
chest disease (Williams, 2006). In the United States, they are
ranked as the eighth most common cause of mortality (Kim
et al., 2002). Currently, no antifibrotic therapies for chronic liver
disease have been approved by the Food and Drug Administra-
tion (Cohen-Naftaly and Friedman, 2011), and where the
underlying cause of the liver disease cannot be ameliorated,
therapeutic options are limited to addressing the consequent
complications, such as portal hypertension, hepatocellular car-
cinoma, and liver failure. Therefore, a greater understanding
of molecular mechanisms regulating the hepatic fibrogenic
response in liver is needed for the identification of novel targets
for successful antifibrotic therapies.
The central players in liver fibrosis are nonparenchymal cells
such as hepatic stellate cells (HSCs) (Bataller and Brenner,
2005; Bouwens et al., 1992), which are the main producers of
ECM (Friedman, 2008; Friedman et al., 1985; Reynaert et al.,
2002). In the healthy liver, HSCs are retinoid (vitamin A) storage
cells located in the space of Disse, between the sinusoidal endo-
thelium and hepatocytes (Friedman, 2008). Following injury,
paracrine stimuli cause HSCs to undergo dramatic phenotypic
changes (in a process called activation), whereby they exhibit
proliferation, contractility, and loss of retinoid stores, accompa-
nied by secretion of chemokines, cytokines, and pathological
ECM components (Friedman, 2008; Geerts, 2001). While the
precise mechanisms regulating this process have yet to be
elucidated, transforming growth factor (TGF) b1 signaling is
recognized as one of the most potent profibrotic pathwaysCell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc. 601
Figure 1. Systemic Administration of Calcipotriol Attenuates Liver Fibrosis in CCl4-TreatedMice, whereas Genetic Abrogation of VdrResults
in Spontaneous Liver Fibrosis
(A) Livers from 4-week-treated C57BL/6J mice (vehicle [DMSO, n = 3], carbon tetrachloride [CCl4, 0.5 ml/kg IP, n = 6], calcipotriol [Cal, 20 mg/kg oral gavage,
n = 3], and CCl4 plus calcipotriol [n = 6]) stained with Sirius red (left) and hematoxylin and eosin (H&E, right). Scale bar, 200 mm.
(B–D) Fibrosis quantified by (B) Sirius red staining, (C) hydroxyproline content, and (D) H&E staining (Ishak score). Asterisks denote statistically significant
differences (Student’s unpaired t test: **p < 0.01; ***p < 0.001).
(legend continued on next page)
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responsible for ECM synthesis (Breitkopf et al., 2006; Inagaki
and Okazaki, 2007).
TGFb is amultifunctional cytokinewith profound effects on cell
division, differentiation, migration, adhesion, organization, and
death. There are three major isoforms of TGFb (TGFb1, TGFb2,
and TGFb3), and TGFb1 is the principal isoform implicated in
liver fibrosis (Inagaki and Okazaki, 2007). Following liver injury,
TGFb1, derived from both paracrine and autocrine sources,
binds to type I and type II serine/threonine receptor kinases on
the cell surface of HSCs (Inagaki and Okazaki, 2007). Subse-
quently, its downstream effectors SMAD2 and SMAD3 are
phosphorylated and released into the cytosol, where they form
a complex with SMAD4. This SMAD complex can then translo-
cate into the nucleus, recognize SMAD-binding elements (SBE)
on the genome, and directly regulate target genes (Feng and
Derynck, 2005; Massague´ et al., 2005). Thus, deciphering the
TGFb/SMAD transcriptional network in HSCs and understanding
how it can be controlled by extracellular and intracellular factors
are key to the development of effective antifibrotic strategies.
The vitamin D receptor (VDR) is a member of the nuclear
hormone receptor (NHR) superfamily and is a key regulator of
calcium homeostasis and skeletal health (Bouillon et al., 2008;
Goltzman et al., 2004). The endogenous activators of this recep-
tor are the biologically active form of vitamin D (1,25(OH)2D3) and
bile acids such as lithocholic acid (LCA) and its derivatives (LCA-
acetate, LCA-formate, 3-keto LCA) (Makishima et al., 2002;
Nagpal et al., 2005). Interestingly, the closest structural and
functional relatives of VDR within the NHR superfamily include
farnesoid X receptor (FXR), constitutive androstane receptor
(CAR), and pregnane X receptor (PXR), all of which are regulators
of bile acid homeostasis and xenobiotic detoxification in the liver
(Bookout et al., 2006; Bouillon et al., 2008). However, a physio-
logical role for vitamin D in hepatic function has long been dis-
missed due to low levels of VDR expression in liver (Bookout
et al., 2006; Han et al., 2010). Nonetheless, the finding of robust
VDR expression in HSCs led us to consider it as a possible
modulator of liver fibrosis (Gascon-Barre´ et al., 2003).
Here, we demonstrate that liver fibrosis in a standard mouse
model of hepatic injury can be ameliorated by administration of
the synthetic VDR agonist calcipotriol, which reduces both
collagen deposition and fibrotic gene expression. We also
show that Vdr knockout mice develop spontaneous liver fibrosis,
proving a role for this receptor in normal liver homeostasis.
Mechanistic studies revealed that activation of VDR signaling
antagonizes a wide range of TGFb/SMAD-dependent transcrip-
tional responses on profibrotic genes in HSCs. Mapping of
genome-wide binding sites of VDR and SMAD3 revealed over-
lapping DNA occupancy of these transcription factors on cis-
regulatory elements of profibrotic genes. Interestingly, TGFb/(E–G) qRT-PCR measurement of hepatic gene expression levels of Col1a1, Tgfb
significant differences (Student’s unpaired t test: **p < 0.01; ***p < 0.001).
(H) Sirius red (top) and H&E (bottom) stained liver sections from Vdr+/+ (n = 3), Vdr+
supplemented rescue diet (2% calcium, 1.25%phosphorus, 20% lactose) for 6m
inflammatory cell infiltrate (Vdr/ mice), respectively. Scale bar, 50 mm.
(I) Fibrosis quantified by hydroxyproline content and (J) Col1a1mRNA expression u
red staining (refer to Results). Data represent the mean ±SEM. Asterisks denote
See also Figures S1 and S2.SMAD signaling enhanced the accessibility of liganded VDR
with these genomic loci, which in turn antagonized recruitment
of SMAD3. This dynamic VDR/SMAD genomic feedback circuit
represents a previously unrecognized mechanism for regulating
hepatic fibrogenesis.
RESULTS
VDR Prevents Liver Fibrosis
Consistent with previous results (Abramovitch et al., 2011;
Gascon-Barre´ et al., 2003), we found that Vdr is expressed in
HSCs but is not detectable in either whole liver or purified
hepatocytes (Figures S1A–S1C available online). Moreover, the
HSC-expressed VDR is fully functional as determined by ligand
induction of CYP24A1 expression by either 1,25(OH)2D3 or its
low-calcemic analog, calcipotriol (Cal) (Nagpal et al., 2005) (Fig-
ure S2A), in both primary HSCs and LX-2 cells, a well-estab-
lished TGFb1-responsive human HSC cell line (Xu et al., 2005)
(Figures S1D and S1E).
To address whether VDR signaling could suppress fibrotic
gene expression and counteract hepatic fibrogenesis in vivo,
liver fibrosis was induced by carbon tetrachloride (CCl4), a widely
used hepatotoxic agent, at a dose of 0.5 ml/kg administered by
intraperitoneal (IP) injection three times per week in wild-type
C57BL/6J mice. By 4 weeks, CCl4-treated mice exhibited exten-
sive liver bridging fibrosis with substantial collagen deposition,
whereas CCl4/calcipotriol-cotreated mice had a significant
reduction in fibrosis as demonstrated by quantitation of Sirius
red staining, hepatic hydroxyproline content, and histological
fibrotic scoring (Figures 1A–1D). The serum calcium concentra-
tion was not significantly altered by calcipotriol treatment (Fig-
ure S2B). Examination of key fibrotic marker genes such as
Col1a1, Tgfb1, and Timp1 revealed between 50% and 70%
downregulation by calcipotriol (Figures 1E–1G). Interestingly,
when the mice were pretreated with calcipotriol for 5 weeks prior
to CCl4/calcipotriol-cotreatment, the fibrogenic response in liver
was nearly completely abrogated (Figures S2C–S2F), suggest-
ing that the VDR agonist possesses not only the ability to atten-
uate fibrosis but also the potential to proactively prevent liver
fibrosis in vivo.
This led us to examine whether VDR deficiency could impact
liver fibrogenesis. Indeed, 6-month-old Vdr/ mice exhibited a
spontaneous liver injury/fibrosis phenotype as demonstrated
by increased collagen deposition, with two of four mice devel-
oping frank cirrhosis (Figure 1H, right/top) associated with hepa-
tocyte necrosis and foci of necroinflammation surrounding portal
tracts (Figure 1H, right/bottom, arrow). As there was some
variability in the degree of liver fibrosis observed using Sirius
red staining of liver sections, liver hydroxyproline content was1, and Timp1. Data represent the mean ±SEM. Asterisks denote statistically
/ (n = 4), and Vdr/ (n = 2 of 4) micemaintained on a calcium- and phosphate-
onths prior to sacrifice. Arrows indicate perisinusoidal fibrosis (Vdr+/mice) and
sing the two of four livers from Vdr/mice exhibiting the least fibrosis on Sirius
statistically significant differences (Student’s unpaired t test: *p < 0.05).
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A B C Figure 2. VDR Signaling Suppresses
TGFb-Induced Profibrotic Genes
(A) Heatmap comparing 519 differentially ex-
pressed genes in freshly isolated rat HSCs
(quiescent HSCs, Q-HSCs), activated HSCs
(A-HSCs, 3 days culture on plastic), and cell
cultures in the presence of 10 nM 1,25(OH)2D3
[A-HSCs + 1,25(OH)2D3]. Euclidean clustering of
both rows and columns using log2-transformed
microarray expression data; n = 2 per treatment
group.
(B) Heatmap of fold change of genes involved in
fibrosis in primary rat HSCs treated with TGFb1
(1 ng/ml) and TGFb1 plus 1,25(OH)2D3 (100 nM) for
24 hr; n = 2 per treatment group.
(C) Fibrotic gene expression in control (siCNTL) or
VDR-specific (siVDR) siRNA-transfected LX-2 cells
treated with vehicle (DMSO), calcipotriol (Cal,
100 nM), TGFb1 (1 ng/ml), or TGFb1 plus Cal for
16 hr. Data represent the mean ±SEM of at least
three independent experiments performed in
triplicate. Asterisks denote statistically significant
differences (Student’s unpaired t test: *p < 0.05;
**p < 0.01).measured in the two Vdr/ mice exhibiting the least fibrosis
(noncirrhotic mice) and was still found to be significantly greater
than that observed in either wild-type or Vdr+/ mice (Figure 1I).
Moreover, Vdr+/ mice exhibited multiple foci of perisinusoidal
fibrosis in the absence of an inflammatory response (Figure 1H,
center/top, arrows), a pathology not observed in control wild-
type mice maintained on an identical calcium- and phosphate-
supplemented diet (Figure 1H, left). Histological findings were
confirmed by quantitation of hepatic hydroxyproline content
as well as examination of key fibrotic marker gene, Col1a1 (Fig-
ures 1I and 1J). These data suggest that both Vdr alleles are
required for the maintenance of normal liver architecture and
that when completely abrogated, the result is loss of control of
the local inflammatory response in addition to dysregulation of
fibrogenesis.
VDR Signaling Suppresses TGFb-Induced Profibrotic
Genes
Expression profiling was used to explore the potential impact of
VDR signaling in TGFb1 and TGFb1 plus 1,25(OH)2D3-treated
primary rat HSCs. Notably, 1,25(OH)2D3 treatment attenuated
the culture-induced activation of HSCs, such that the tran-
scriptome of treated cells closely resembled that of freshly
isolated quiescent cells (Figure 2A) and cotreatment of
1,25(OH)2D3 together with TGFb1 resulted in considerable
repression of a large set of TGFb1 induced genes (Table S1).
Among these, we noted 39 genes central to hepatic fibrogene-
sis, including collagens (Bataller and Brenner, 2005; Tsukada
et al., 2006), Tgf superfamily members (Inagaki and Okazaki,
2007), matrix metalloproteinase family members (Mmps)
(Arthur, 2000; Han, 2006), tissue inhibitors of metalloproteinase
(Timps) (Arthur, 2000; Yoshiji et al., 2002), integrins (Patsenker
and Stickel, 2011), and lysyl oxidase family members (Barry-604 Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc.Hamilton et al., 2010; Kagan and Li, 2003; Vadasz et al.,
2005) (Figure 2B).
Next, we confirmed that calcipotriol potently repressed fibrotic
gene expression in both primary mouse HSCs and LX-2 cells,
suggesting that the anti-TGFb properties of VDR agonists are
likely conserved across mammalian species (data not shown
and Figure 2C). Finally, using RNA interference (RNAi) in LX-2
cells, we found that loss of VDR abolished calcipotriol-mediated
repression of TGFb1-induced gene expression (Figure 2C),
collectively revealing that VDR regulates an anti-TGFb/fibrotic
network in vitro.
Defining VDR and SMAD3 Cistromes in HSCs
Amajor question raised by these observations was whether VDR
was a direct or indirect regulator of the antifibrotic gene network.
As SMAD2 and SMAD3 are required for TGFb1-induced profi-
brotic gene expression in HSCs (Figure S3A) and VDR activation
did not significantly affect TGFb1-induced phosphorylation and
subsequent nuclear translocation of SMAD3 (Figure S3B), we
proposed a direct regulatory role for VDR. To explore this possi-
bility, we analyzed the genome-wide binding sites of VDR
and SMAD3 in LX-2 cells cultured with both calcipotriol and
TGFb1 using chromatin immunoprecipitation coupled with
high-throughput deep sequencing (ChIP-seq). The resulting cis-
tromes identified 24,984 VDR and 23,581 SMAD3 high-confi-
dence binding sites (false discovery rate [FDR] < 0.0001) (Figures
3A and 3E). Consistent with the reported global binding pattern
for other transcription factors (Barish et al., 2010; Biddie et al.,
2011; Heinz et al., 2010; Trompouki et al., 2011), the majority
of VDR- and SMAD3-binding sites localize to distant intergenic
and intronic regions, whereas only 16%–21% are found at
gene promoters (Figures 3A and 3E). From the list of VDR-





Figure 3. VDR and SMAD3 Cistromes in Hepatic Stellate Cells
(A and E) Pie charts illustrating genomic locations of VDR- and SMAD3-binding sites in treated LX-2 cells (100 nM calcipotriol and 1 ng/ml TGFb1 for 4 hr following
16 hr 100 nM calcipotriol pretreatment; FDR < 0.0001). Promoter regions, <2 kb from the transcription start site; intergenic regions, not promoter, intron, or exon.
(B and F) Representative ChIP-seq reads for VDR and SMAD3 aligned to the CYP24A1 and ID1 genes, respectively.
(C and G) Gene ontology (GO) classification of genes annotated with VDR- and SMAD3-binding sites.
(D and H) De novo motif analysis performed on sequences located within 100 bp of VDR and SMAD3 peaks (FDR < 0.0001).
See also Figures S3 and S4.characterized functional vitamin D response elements (VDRE) for
known vitamin-D-inducible genes, such asCYP24A1 (Figure 3B),
SPP1, and BGLAP (Figures S4A and S4B), and SBE for TGFb
signaling target genes, including ID1 (Figure 3F), SMAD7, and
TGFbI (Figures S4C and S4D). Gene annotation analysis
assigned peaks based on the proximity to the closest transcrip-
tion start site and yielded 11,031 and 9,210 putative target genes
within the individual VDR and SMAD3 cistromes, respectively.
Gene ontology (GO) analysis of these annotated genes revealed
that the most common classified functions for putative VDR and
SMAD3 target genes were metabolism (47%) and cell signaling
(34%) (Figures 3C and 3G).
Finally, we interrogated themost significantly enriched binding
motifs for VDR and SMAD3. Among these sequence signatures,
a direct hexamer repeat with a 3 bp spacer (DR3) consensus
sequence was the most enriched motif at VDR sites, explaining
74% of VDR binding peaks (Figure 3D, top), while the consensus
SBE sequence, a GTCT motif, accounted for 83% of SMAD3
binding peaks (Figure 3H, top). Interestingly, our analysis re-
vealed that the GTCT and DR3-type motifs are also coenriched
within nucleosomal distance at VDR- and SMAD3-binding sites,respectively, suggesting that VDR and SMAD3 communicate via
intersecting cistromes (Figures 3D and 3H, bottom).
Antagonism of TGFb Signaling via VDR/SMAD3Genomic
Crosstalk
To address this possibility, we used bioinformatic analysis to
quantify the extent of cistrome intersection by calculating the
number of sites bound by both VDR and SMAD3. A total of
10,436 genomic sites were co-occupied (Figure 4A), and the
co-occupancy pattern is genome-wide as visualized by a heat-
map quantifying VDR sites surrounding SMAD3 binding peaks
(Figure 4B). If this genomic intersection mediates VDR/SMAD3
crosstalk, then VDR and SMAD3 could interact with their co-
occupied sites simultaneously. Sequential ChIP (ChIP-re-ChIP)
experiments confirmed that VDR and SMAD3 can, at least tran-
siently, co-occupy the same genomic sites (Figure 4C).
Next, if anti-TGFb signaling is mediated by a VDR/SMAD
genomic intersection, then profibrotic genes in HSCs should
be overrepresented in jointly bound regulatory elements. Indeed,
GO analysis designating human phenotypes showed significant
enrichment of ‘‘abnormal scarring’’ response (67%) for lociCell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc. 605
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Figure 4. Antagonism of TGFb Signaling via VDR/SMAD3 Genomic Crosstalk
(A) Venn diagram depicting overlap of VDR and SMAD3 genomic binding sites in LX-2 cells treated as in Figure 3.
(B) Intensity plots showing hierarchical clustering of ChIP-fragment densities as a function of distance from the center of statistically significant SMAD3 binding
peaks (23,532 peaks; FDR = 0.0001). Intensity around position 0 of VDR (blue) indicates overlapping VDR/SMAD3 sites with SMAD3 (red) acting as a positive
control.
(C) ChIP-re-ChIP of treated LX-2 cells analyzed by qPCR at VDR and SMAD3 cobound sites. Occupancy is expressed relative to input chromatin.
(D) Common human phenotypes enriched in genes co-occupied by VDR and SMAD3.
(E) The number of TGFb1/VDR-coregulated profibrotic genes harboring genomic sites co-occupied by VDR and SMAD3.
(F) The number of VDR/SMAD3 co-occupied sites observed in profibrotic genes coregulated by TGFb1 and VDR. LX-2 cells treated as in Figure 3. Data represent
the mean ±SEM of at least three independent experiments performed in triplicate. Asterisks denote statistically significant differences (Student’s t test: *p < 0.05;
**p < 0.01).
See also Table S2 and Figure S5.co-occupied by VDR and SMAD3 (Figure 4D), leading us to
examine potential VDR/SMAD3 co-occupancy with the earlier
identified 39 profibrotic genes (Figure 2B). Within this subset,
34 were found to contain VDR/SMAD3 co-occupied sites (Fig-
ure 4E). Furthermore, many of these genes were found to contain
multiple VDR/SMAD3 co-occupied sites (Figure 4F; Table S2).
Finally, we engineered luciferase reporter plasmids bearing
VDR/SMAD3-cobound sites on the COL1A1 gene and showed
that these genomic elements could at least partially recapitulate
the opposing actions of calcipotriol and TGFb1, suggesting that
these cis-elements function as enhancers of profibrotic gene
expression (Figure S5A).
VDR/SMAD Genomic Antagonism
Informatic analysis of the spatial relationships between VDR
and SMAD3 in co-occupied genomic regions confirmed that
their respective response elements were colocalized within606 Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc.one nucleosomal window (%200 base pairs) (Figure S5B), further
supporting the possibility of genomic antagonism by proximal
DNA binding (Barish et al., 2010; Hua et al., 2009).
The presence of VDR/SMAD genomic antagonism can be
visualized by plotting the average ChIP-seq signal intensity of
VDR and SMAD3 to the center of their co-occupied sites. This
demonstrated that, in the presence of calcipotriol, TGFb-in-
duced recruitment of SMAD3 was globally compromised by
1.5-fold, whereas binding of VDR to these sites was globally
enhanced by nearly 10-fold (Figures 5A and 5B). In addition,
the proposed genomic antagonism was illustrated by examining
its impact along a profibrotic gene harboring VDR/SMAD co-
occupied regulatory elements such as COL1A1. Visualization
of sequencing tracks revealed that calcipotriol promoted VDR
occupancy at all three major VDR/SMAD3-cobound sites on
the COL1A1 gene (Figure 5C, middle two tracks). In contrast,
TGFb-induced SMAD3 binding was typically diminished along
Figure 5. Genomic Antagonism between VDR and SMAD
(A and B) Plots of VDR and SMAD3 ChIP-seq signal intensity relative to the center of VDR/SMAD3 co-occupied sites in LX-2 cells (1 ng/ml TGFb1 ± 100 nM
calcipotriol for 4 hr).
(C) Representative ChIP-seq reads aligned to COL1A1 for VDR and SMAD3 in treated LX-2 cells (vehicle [DMSO], 100 nM calcipotriol [Cal], 1 ng/ml TGFb1, or
TGFb1 plus calcipotriol). The three co-occupied sites are designated as 1, 2, and 3.
(D and F) ChIP-qPCR at COL1A1 regulatory region #1 cobound by VDR and SMAD3 in LX-2 cells treated as above.
(E and G) ChIP-qPCR at COL1A1 regulatory region #1 of control (siCNTL), VDR-specific (siVDR), or SMAD3-specific (siSMAD3) siRNA-transfected LX-2 cells
treated as above. Occupancy is expressed relative to input chromatin. Data represent the mean ±SEM of at least three independent experiments performed in
triplicate. Asterisks denote statistically significant differences (Student’s t test: p < 0.05; **p < 0.01).
See also Figures S6 and S7.the gene upon calcipotriol treatment (Figure 5C, top two tracks,
and independently validated by ChIP quantitative PCR [ChIP-
qPCR], Figures 5D and 5F). Similar loss of SMAD3 coupled
with VDR recruitment was also observed at the regulatory
regions of other profibrotic genes such as COL1A2, TGFB1,
TGFB2, TIMP1, TIMP2, and LOXL2 (Figures S6A–S6F). Further-
more, RNAi-mediated depletion of VDR and SMAD2/3 reversed
the calcipotriol-dependent loss of SMAD3 recruitment and
TGFb1-induced VDR binding to co-occupied regulatory ele-
ments, respectively, demonstrating that VDR and SMADs
are required to mediate this genomic antagonism (Figures 5E
and 5G).
Since recruitment of histone-modifying cofactors such as CBP
and p300 and hyperacetylation of histone H3 have been estab-
lished as landmark events in the activation of TGFb signaling
(Massague´ et al., 2005), we asked whether VDR/SMAD genomic
antagonism could restrain TGFb signaling by interfering with this
epigenetic pathway. We therefore examined the status of his-tone H3 acetylation as well as recruitment of CBP and p300
to VDR/SMAD co-occupied sites in cells treated with either
calcipotriol or TGFb1 or both. ChIP-qPCR demonstrated that
TGFb1 induced recruitment of p300 and CBP and histone H3
hyperacetylation at the VDR/SMAD co-occupied regulatory
region of COL1A1. This effect was lost in cells cotreated with
calcipotriol and TGFb1 (Figure S7A), suggesting that VDR/
SMAD genomic antagonism limits TGFb activation by compro-
mising coactivator recruitment and histone hyperacetylation.
Ligand-dependent corepressor recruitment or ‘‘transrepres-
sion’’ has been proposed as the major mechanism for nuclear
receptors such as PPARg and LXR to negatively regulate inflam-
matory gene expression (Glass and Saijo, 2010). To test whether
transrepression contributes to the antagonism,we examined po-
tential induced recruitment of corepressors, including NCoR,
SMRT, HDAC3, CoREST, LSD1, and G9a, to VDR/SMAD3
co-occupied regulatory regions of profibrotic genes, such as
COL1A1 and COL1A2, in response to calcipotriol and TGFb1.Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc. 607
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Figure 6. TGFb Unmasks a Signal-Dependent VDR Cistrome
(A) Venn diagram displaying overlapping VDR cistromes in treated LX-2 cells (FDR < 0.0001).
(B) Plot of VDRChIP-seq peak locations depicted in (A) categorized as VDRCal/TGFb1 plus Cal (3,537 overlapping), VDRCal only (2,744 calcipotriol only), or VDR
TGFb1 plus Cal only (21,447 calcipotriol plus TGFb1 only) relative to the center of SMAD3-binding sites in LX-2 cells.
(C) Plot of VDR ChIP-seq signal intensity relative to the center of VDR/SMAD3 co-occupied sites in LX-2 cells treated as indicated.
(D) Western blot for VDR in nuclear and whole-cell extracts (NE, WCE) from LX-2 cells treated as above. TFIIH (p89) was used as a loading control.
(E) The percentages of calcipotriol-only, calcipotriol plus TGFb1-only, or calcipotriol/calcipotriol plus TGFb1-overlapping VDR ChIP-seq peaks containing
VDREs.
(F) Plot of histone H3 ChIP-seq signal intensity relative to the center of VDR/SMAD3 co-occupied sites in LX-2 cells treated as indicated.
See also Figure S6.However, altered binding of these corepressors to these sites
could not be detected (Figure S7B), suggesting that the loss of
transcriptional activation complexes from these sites is not due
to increased corepressor recruitment.
TGFb Unmasks a Signal-Dependent VDR Cistrome
While establishing VDR/SMAD3 genomic antagonism, we
noticed that TGFb/SMAD signaling appears to enhance liganded
VDR recruitment to the cis-regulatory regions of COL1A1 (Fig-
ures 5F and 5G). To determine whether this effect is observed
at other VDR-binding sites of profibrotic genes, we analyzed
the VDR cistrome ± calcipotriol in the presence and absence
of TGFb1. Examination of binding data demonstrated that
TGFb1 promotes binding of liganded VDR, but not unliganded
VDR, to cis-regulatory regions at all profibrotic genes (Figure 5B;
Figures S6A–S6F, lower four tracks).
Next, we compared calcipotriol-induced VDR global binding
patterns in the presence or absence of TGFb1. While 6,281 bind-
ing sites comprise the de novo VDR cistrome in the absence of608 Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc.TGFb1, a new cistrome composed of 24,984 sites was induced
in the presence of TGFb1 (Figure 6A). Interestingly, only 3,537
sites were shared by both cistromes, and 85% (21,447 sites) of
the TGFb-induced liganded VDR-binding sites were unique (Fig-
ure 6A), suggesting that TGFb results in a dramatic shift of
genome-wide binding locations of liganded VDR.
Comparative studies of the two VDR cistromes revealed that
TGFb1 plus calcipotriol sites (but not calcipotriol-only sites)
were highly enriched at SMAD3-binding sites (Figure 6B). More-
over, binding of VDR to these genomic sites was enhanced by
TGFb signaling (Figure 6C), and this effect was not likely due to
a change of VDR expression (Figure 6D). We next analyzed the
DNA sequences of different subsets of VDR genomic loci and
found more than 70% contain de novo VDR regulatory sites
(Figure 6E), suggesting that VDR acts directly on the DNA,
as opposed to SMAD-dependent tethering. Interestingly, we
observed that TGFb induced significant depletion of nucleo-
somes at VDR-SMAD3 cobound sites (Figure 6F), indicating
that TGFb-SMAD signaling may promote binding of VDR to its
Figure 7. VDR/SMAD Genomic Circuit
(A and B) Time course of VDR and SMAD3 binding at the COL1A1 regulatory region #1 in treated LX-2 cells (vehicle [DMSO], 100 nM calcipotriol, 1 ng/ml TGFb1,
1 ng/ml TGFb1 plus 100 nM calcipotriol) determined by ChIP-qPCR. LX-2 cells were pretreated with calcipotriol (100 nM) for 16 hr prior to time course assay and
occupancy is expressed relative to input chromatin. Data represent the mean ±SEM of at least three independent experiments performed in triplicate. Asterisks
denote statistically significant differences compared to calcipotriol-induced VDR occupancy or TGFb1-induced SMAD3 occupancy of corresponding time point
(Student’s unpaired t test: *p < 0.05; *p < 0.01).
(C) Time course of TGFb1 plus calcipotriol-induced VDR and SMAD3 binding, normalized to calcipotriol alone or TGFb1 alone, respectively. Data represent the
mean ±SEM of at least three independent experiments performed in triplicate.
(D) Model depicting proposed VDR/SMAD genomic circuit controlling profibrogenic responses in HSCs.adjacent sites by potentiating local chromatin remodeling and
resultant accessibility.
The Genomic Circuit between VDR and SMAD
Our findings suggest a dynamic relationship between VDR and
TGFb/SMAD signaling; perhaps TGFb induction of SMAD bind-
ing to chromatin creates a new genomic landscape that now
becomes accessible to liganded VDR, which could enable
temporally delayed SMAD repression. To explore this spatiotem-
poral relationship, we determined the kinetics of SMAD3 and
VDR recruitment to co-occupied cis-regulatory elements of
fibrotic genes (such as COL1A1) in the presence of either calci-
potriol or TGFb1 or both. Specifically, ChIP-qPCRwas employed
to monitor binding of VDR and SMAD3 to the cis-regulatory re-
gion of COL1A1 at multiple time points (0, 1, 2, 4, 6, and 16 hr).
Notably, binding of both liganded VDR and SMAD3 to this sitewas maximally promoted by TGFb1 after 4 hr of treatment, fol-
lowed by a gradual decrease to basal levels after 16 hr (Figures
7A ad 7B), confirming the role of TGFb1 in facilitating recruitment
of VDR to chromatin. Interestingly, the binding curve of SMAD3
upon TGFb1 stimulation was dramatically shifted by the pres-
ence of calcipotriol, with the maximum binding of SMAD3
observed just 1 hr post-TGFb1 treatment. After 4 hr, SMAD3
recruitment was significantly reduced by 70% (Figure 7B).
Furthermore, normalization of VDR and SMAD3 binding in the
presence of both calcipotriol and TGFb1 to their basal levels re-
vealed that the occupancy of VDR and SMAD3 were inversely
correlated (Figure 7C), suggesting TGFb-induced chromatin
accessibility produces a genomic architecture that facilitates
VDR to reverse SMAD activation. Together, this VDR/SMAD
genomic circuit provides a chromatin-based mechanism for
VDR to block fibrosis by antagonizing TGFb signaling in HSCs.Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc. 609
DISCUSSION
The establishment of HSCs as the primary effector cell for the
deposition of ECM in normal and fibrotic liver in the early
1990s was a milestone discovery in understanding the patho-
genesis of hepatic fibrosis (Friedman, 1993). Since then, a
wide spectrum of cellular signaling molecules, hormones, cell
membrane receptors, and transcription factors in HSCs have
been investigated and found to promote hepatic fibrogenesis
(Hernandez-Gea and Friedman, 2011). However, the factors
and signaling cascades that actively prevent this pathological
process are poorly understood. Here, we demonstrate that phar-
macological activation of VDR attenuates the progression of liver
fibrosis in an experimental animal model while genetic abroga-
tion of VDR expression results in the spontaneous development
of liver fibrosis, thus implicating VDR in an endocrine checkpoint
that negatively modulates the wound-healing response in liver.
Mechanistically, we delineate a previously unrecognized and
temporally controlled genomic circuit composed of the opposing
action of VDR and SMAD transcription factors that is able to
restrain the intensity of the fibrogenic response in HSCs and
govern fibrogenesis in liver. Specifically, in response to liver
injury, HSC activation by TGFb1 induces profibrotic gene
expression via SMAD translocation to the nucleus and chromatin
remodeling. By increasing accessibility to adjacent VDREs,
SMAD activation facilitates VDR recruitment to previously
cryptic genomic sites. Liganded VDR subsequently antagonizes
SMAD residency on chromatin and compromises acetylation of
histone H3 to ultimately suppress profibrotic gene expression
(Figure 7D). Notably, the proximal location of nearly 10,500
TGFb1-induced SMAD- and VDR-binding sites identifies a global
chromatin architecture and suggests that the integrated VDR/
SMAD genomic circuit functions as a master regulator of the
hepatic fibrotic response.
The identification of a chromatin basis for inhibiting TGFb
signaling places a direct focus on SMAD-dependent transcrip-
tion as a regulatory target. This is relevant because TGFb/
SMAD signaling plays an essential role in almost every aspect
of metazoan biology, and its dysregulation can result in a diver-
sity of human diseases ranging from autoimmunity to fibrosis
and cancer (Hernandez-Gea and Friedman, 2011; Li and Flavell,
2008; Massague´, 2008). Our finding of genomic antagonism
between VDR and SMAD not only establishes VDR as the first
DNA binding transcription factor that attenuates TGFb/SMAD
signaling at a chromatin interface, but also adds specificity (a
cistromic layer) for the more general concept of ‘‘transcriptional
crosstalk.’’
The observation that TGFb-SMAD activation enables subse-
quent recruitment of ligand-bound VDR to repress SMAD targets
reveals a means by which two endogenous signaling pathways
can cross-regulate each other’s activity. Thus, this genomic
relay allows positive activation by SMAD to be subsequently in-
hibited by VDR and thus constitutes a self-adjusting genomic cir-
cuit, which is highly distinguishable from the previously reported
genomic crosstalk between transcription factors in a mutually
exclusive manner (Barish et al., 2010; Hua et al., 2009). It seems
logical that this circuit may confer on HSCs the ability to orches-
trate ECM synthesis in both the normal and fibrotic liver.610 Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc.In addition to the TGFb/SMAD pathway, fibrosis is almost
always preceded by persistent inflammation clinically (Hernan-
dez-Gea and Friedman, 2011; Lee and Friedman, 2011). Hence,
a broader anti-inflammatory role for VDR signaling might
conceivably contribute to its antifibrotic property in the liver. In
this regard, VDR has been documented for its expression in
several cell types central to the inflammatory response (Barish
et al., 2005; Griffin et al., 2001; von Essen et al., 2010), and
both vitamin D deficiency and polymorphisms of VDR itself as
well as genes involved in vitamin Dmetabolism have been linked
to both the risk and severity of inflammatory diseases (Agmon-
Levin et al., 2012; Janssens et al., 2011; Munger et al., 2006;
Ramagopalan et al., 2011). However, the role of VDR signaling’s
anti-inflammatory action in the context of hepatic fibrogenesis is
far less clear. On one hand, the dysregulated inflammatory
response coupled with the spontaneous development of liver
fibrosis in Vdr/mice suggests that VDR signalingmight control
hepatic fibrogenesis through an anti-inflammatory mechanism
(Figure 1H, right). On the other hand, this notion is blunted by
themodest perisinusoidal liver fibrosis phenotypewithout any in-
flammatory response found in Vdr+/ mice (Figure 1H, center).
Furthermore, the causable relationship between inflammation
and fibrosis remains to be fully established and the major profi-
brogenic role of inflammation during hepatic fibrogenesis
appears to be to sensitize HSCs for TGFb/SMAD activation
(Seki et al., 2007; Seki and Schnabl, 2012). It is therefore unlikely
that the anti-inflammatory property of VDR signaling plays a
major role in its antifibrotic function.
Our studies further serve to clarify an unappreciated function
of VDR signaling in liver pathophysiology. Due to its exception-
ally low expression, VDR has received much less attention than
its highly expressed cognate clade members that include FXR,
PXR, and CAR that impact nearly every aspect of hepatic func-
tion including lipid and glucose metabolism, drug disposition,
cholesterol efflux, and bile acid homeostasis (Bookout et al.,
2006; Chawla et al., 2001). However, recent studies showing
that low vitamin D levels are linked to increased hepatic fibrosis
in patients with chronic liver disease (Abramovitch et al., 2011;
Lim and Chalasani, 2012; Petta et al., 2010; Terrier et al., 2011)
and that vitamin D can inhibit liver fibrosis in rats (Abramovitch
et al., 2011) suggest a potential physiologic role for hepatic
VDR. However, whether and how VDR directly or indirectly
regulates hepatic fibrogenesis remained unresolved. Our find-
ings that VDR promotes HSC quiescence and controls TGFb
signaling identify a new mechanism through which vitamin D
can exert its antifibrotic effects. It is noteworthy that our
delineation of a VDR signaling pathway to inhibit fibrosis is
also consistent with recent studies suggesting that a polymor-
phism in VDR is correlated with increased progression of liver
fibrosis and evolution of cirrhosis (Baur et al., 2012; Tanaka
et al., 2009).
Up to 45% of deaths in the developed world can be attributed
to fibrotic diseases, yet few antifibrotic drugs are currently
approved for clinical use (Wynn, 2008). Though therapies
designed to neutralize TGFb show broad antifibrotic activity
(Rosenbloom et al., 2010), the benefits are compromised by un-
necessarily blocking TGFb in nondiseased tissue. Our discovery
of the VDR/SMAD genomic circuit illuminates a potentially safer
antifibrotic strategy by restricting TGFb inhibition to VDR-posi-
tive cells instead of perturbing signaling body-wide.
In summary, our work describes an intersecting genomic
circuit comprising VDR and SMAD transcription factors that
governs hepatic fibrogenesis. This finding significantly extends
our understanding of how two distinct signal-dependent
transcription factors interact with each other to establish cell
identity and function. Through the use of genetic and inducible
models, we provide new insight into how global programs
responding to TGFb1 signaling are established and regulated.
Furthermore, these studies establish VDR as a potential drug
target to treat liver fibrosis and provide a new paradigm of
VDR-dependent gene expression regulation. Given the ubiqui-
tous expression patterns of VDR and TGFb, the VDR/SMAD
genomic circuit is likely to be applicable to many other cell types
and may impact the pathogenesis of a wide range of human
diseases.
EXPERIMENTAL PROCEDURES
All animal experiments were performed in specific pathogen-free facilities at
the Salk Institute following the Institutional Animal Care and Use Committee’s
guidelines.
Primary HSCs Isolation and Culture
HSCs were isolated from 10-week-old male C57BL/6Jmice andWistar rats by
in situ pronase, collagenase perfusion, and single-step Histogenz gradient as
previously reported (Hendriks et al., 1985; Knook et al., 1982). Isolated HSCs
were cultured in Dulbecco’s modified Eagle’s medium (Mediatech) containing
20% fetal bovine serum (Hyclone) on six-well plates for 40 hr prior to end-point
assays.
Immunoprecipitation and Western Blot
The whole-cell lysates were obtained through RIPA buffer lysis while isolation
of nuclear extract was performed as previously reported (Ding et al., 2008).
Total SMAD3 was immunoprecipitated in nuclear extracts from LX-2 cells
using anti-SMAD2/3 antibody (Santa Cruz, sc-133098) followed by SDS-
PAGE and western blot detection by anti-SMAD3 (Cell Signaling, 9523) and
anti-pSMAD3 (Cell Signaling, 9520) specific antibodies.
Cell Culture, Luciferase Assay, and qRT-PCR
LX-2 cells (a generous gift from Professor Scott Friedman, Mount Sinai School
of Medicine, New York, NY) were cultured as described previously (Xu et al.,
2005). TGFb1 (R&D Systems), 1,25(OH)2D3, and calcipotriol (Tocris) were
used at concentrations of 1 ng/ml, 100 nM, and 100 nM, respectively, except
when otherwise indicated. For luciferase assays, DNA transfections were per-
formed using Fugene 6 (Roche) following the manufacturer’s instructions.
Twenty-four hours following DNA transfections, cells were treatedwith vehicle,
calcipotriol, or TGFb1 or both for another 24 hr prior to luciferase/b-galactosi-
dase assays (Promega). For quantitative RT-PCR (qRT-PCR), total RNA was
purified following TRIzol extraction and treated with DNaseI (Life Technolo-
gies). Complementary DNA synthesis was carried out with iScript RT Supermix
(Bio-Rad). Quantitative PCRwas performed in technical triplicates using SYBR
Green reagent (Bio-Rad). The relative standard curve method was used for
quantitation (Bio-Rad). Expression levels were calculated by normalization to
either Gapdh (mouse) or U36B4 (human) quantities. The sequences of primers
are listed in Table S3.
Transfection of siRNAs
Transfection was carried out at a concentration of 20 nM of indicated
small interfering RNAs (siRNAs) (in the case of SMAD2/3, 10 nM of each
siRNA was combined for transfection) using RNAiMax transfection reagent
(Life Technologies). Transfected cells were cultured without perturbation for
at least 48 hr prior to terminal assays.CCl4 Model of Liver Injury and Fibrosis
Eight-week-old male C57BL/6J mice were IP injected with 0.5 ml/kg body
weight CCl4 (1:50 v/v in corn oil from Sigma) or vehicle (DMSO in corn oil) three
times a week for 4 weeks. Calcipotriol (20 mg/kg body weight) was adminis-
tered by oral gavage five times a week, commencing 20 days after the first
dose of CCl4. The animals were terminated 72 hr after the final CCl4 injection,
and whole livers and serum were collected for histological, cytological,
biochemical, and molecular analyses.
Vdr Knockout Mice
C57BL/6J mice heterozygous for targeted ablation of Vdr (Li et al., 1997) were
obtained from The Jackson Laboratory (stock number 006133).Wild-type con-
trols, Vdr+/, and Vdr/mice were maintained on a Vdr/ rescue diet (Amling
et al., 1999) containing 21% calcium, 0.67% phosphorus, and 20% lactose
supplemented with 4.4 U vitamin D per gram diet for 6 months prior to sacri-
fice. Livers were collected for analysis as above.
Fibrotic Score and Quantification of Hepatic Collagen and
Hydroxyproline Content
Sections (5 mm) of formalin-fixed liver were stained following standard
hematoxylin and eosin and Sirius red methods and reviewed by a pathologist
who was blinded to the experimental conditions. Fibrosis was scored using
the Ishak modified histological activity index (HAI) scoring system. Fibrosis
was also quantified using Image J software on ten noncontiguous Sirius-
red-stained sections. All images were obtained using a high-resolution
Leica DFC420 digital camera mounted on an Olympus microscope equipped
with 34/0.13, 310/0.30, 320/0.50, and 340/0.75 UplanFL N plan objective
lenses and processedwith the Leica Application Suite. Hepatic hydroxyproline
content was measured using a commercial colorimetric assay from Biovision
(K555-100).
ChIP and ChIP-Re-ChIP
LX-2 cells were pretreated with calcipotriol (100 nM) for 16 hr followed by incu-
bation of calcipotriol (100 nM) or TGFb1 (1 ng/ml) or both for an additional 4 hr.
Cells were then harvested for the ChIP assay. The experimental procedure for
ChIP was as previously described (Barish et al., 2010). Briefly, after fixation,
nuclei from LX-2 cells were isolated, lysed, and sheared with a Diagenode
Bioruptor to yield DNA fragment sizes of 200–1,000 bp followed by immuno-
precipitation using the following antibodies: normal rabbit immunoglobulin G
(Santa Cruz, sc-2027), VDR (Santa Cruz, sc-1008), SMAD3 (Abcam,
ab28379), and histone H3 (Abcam, ab1791). For ChIP-re-ChIP, after the
first ChIP, the immunoprecipitated DNA-protein complex was eluted from
beads using 10 mM dithiothreitol and diluted 100-fold, followed by the
second ChIP.
ChIP-Seq Data Analysis
The procedure was as previously described (Barish et al., 2010). Briefly, short
DNA reads were aligned against the human hg18 reference genome (NCBI
Build 36.1) using the Illumina Pipeline Suite v1.7. Reads were aligned using
the Bowtie aligner, allowing up to two mismatches in the read. Only tags
that map uniquely to the genome were considered for further analysis. Subse-
quent peak calling and motif analysis were conducted using HOMER, a soft-
ware suite for ChIP-seq analysis. The methods for HOMER, which are
described below, have been implemented and are freely available at http://
biowhat.ucsd.edu/homer/ (Heinz et al., 2010). One tag from each unique posi-
tion was considered to eliminate peaks resulting from clonal amplification of
fragments during the ChIP-seq protocol. Peaks were identified by searching
for clusters of tags within a sliding 200 bp window, requiring adjacent clusters
to be at least 1 kb away from each other. The threshold for the number of tags
that determine a valid peak was selected for an FDR < 0.0001, as empirically
determined by repeating the peak finding procedure using randomized tag
positions. Peaks are required to have at least 4-fold more tags (normalized
to total count) than input or immunoglobulin G control samples and 4-fold
more tags relative to the local background region (10 kb) to avoid identifying
regions with genomic duplications or nonlocalized binding. Peaks are anno-
tated to gene products by identifying the nearest RefSeq transcriptional start
site. Visualization of ChIP-seq results was achieved by uploading customCell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc. 611
tracks onto the University of California, Santa Cruz genome browser. Human
phenotype analysis was performed using GREAT (genomic regions enrich-
ment of annotations tool) at http://great.stanford.edu/.
Microarray Data Analysis
Total RNA from primary rat or mouse HSCswas isolated using the RNeasymini
kit (QIAGEN) according to standard protocols. RNA integrity and quality was
assessed using the Agilent Bioanalyzer and prepared for hybridization to
Illumina rat or mouse gene expression arrays according to standard Illumina
protocols. Feature extractionwas performed using the Illumina GenomeStudio
software. Normalization and identification of differentially expressed genes
from biological duplicates was performed using VAMPIRE at http://
sasquatch.ucsd.edu/vampire/.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the full data sets (ChIP-
seq and microarray) is GSE41580.
SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and three tables and can be
found with this article online at http://dx.doi.org/10.1016/j.cell.2013.03.028.
ACKNOWLEDGMENTS
We thank C. Brondos and E. Ong for administrative assistance, J. Nery for
assistance with DNA sequencing, C. Benner for assistance with HOMER soft-
ware, and H. Juguilon and J. Alvarez for technical assistance. N.D. was sup-
ported by a postdoctoral fellowship from Genentech Foundation. G.D.B.
was supported by grant K08HL092298. This work was funded by grants
from the National Institutes of Health (DK057978, HL105278, DK090962,
HL088093, ES010337, and CA014195) and National Health and Medical
Research Council of Australia project grants 512354 and 632886 (to C.L.
and M.D.), as well as by the Helmsley Charitable Trust, Samuel Waxman
Cancer Research Foundation, and Ipsen/Biomeasure. R.M.E. and M.D. are
supported in part by a Stand Up to Cancer Dream Team translational cancer
research grant, a Program of the Entertainment Industry Foundation (SU2C-
AACR-DT0509). R.M.E is an investigator of the Howard Hughes Medical Insti-
tute and March of Dimes chair in molecular and developmental biology at the
Salk Institute.
Received: October 12, 2012
Revised: January 14, 2013
Accepted: March 11, 2013
Published: April 25, 2013
REFERENCES
Abramovitch, S., Dahan-Bachar, L., Sharvit, E., Weisman, Y., Ben Tov, A., Bra-
zowski, E., and Reif, S. (2011). Vitamin D inhibits proliferation and profibrotic
marker expression in hepatic stellate cells and decreases thioacetamide-
induced liver fibrosis in rats. Gut 60, 1728–1737.
Agmon-Levin, N., Theodor, E., Segal, R.M., and Shoenfeld, Y. (2012). Vitamin
D in Systemic and Organ-Specific Autoimmune Diseases. Clin. Rev. Allergy
Immunol. 2012, 14.
Amling, M., Priemel, M., Holzmann, T., Chapin, K., Rueger, J.M., Baron, R.,
and Demay, M.B. (1999). Rescue of the skeletal phenotype of vitamin D
receptor-ablated mice in the setting of normal mineral ion homeostasis: formal
histomorphometric and biomechanical analyses. Endocrinology 140, 4982–
4987.
Arthur, M.J. (2000). Fibrogenesis II. Metalloproteinases and their inhibitors in
liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 279, G245–G249.
Barish, G.D., Downes, M., Alaynick, W.A., Yu, R.T., Ocampo, C.B., Bookout,
A.L., Mangelsdorf, D.J., and Evans, R.M. (2005). A Nuclear Receptor Atlas:
macrophage activation. Mol. Endocrinol. 19, 2466–2477.612 Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc.Barish, G.D., Yu, R.T., Karunasiri, M., Ocampo, C.B., Dixon, J., Benner, C.,
Dent, A.L., Tangirala, R.K., and Evans, R.M. (2010). Bcl-6 and NF-kappaB cis-
tromes mediate opposing regulation of the innate immune response. Genes
Dev. 24, 2760–2765.
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H.M.,
Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010).
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a
pathologic microenvironment. Nat. Med. 16, 1009–1017.
Bataller, R., and Brenner, D.A. (2005). Liver fibrosis. J. Clin. Invest. 115,
209–218.
Baur, K., Mertens, J.C., Schmitt, J., Iwata, R., Stieger, B., Eloranta, J.J., Frei,
P., Stickel, F., Dill, M.T., Seifert, B., et al. (2012). Combined effect of 25-OH
vitamin D plasma levels and genetic Vitamin D Receptor (NR 1I1) variants on
fibrosis progression rate in HCV patients. Liver Int. 32, 635–643.
Biddie, S.C., John, S., Sabo, P.J., Thurman, R.E., Johnson, T.A., Schiltz, R.L.,
Miranda, T.B., Sung, M.H., Trump, S., Lightman, S.L., et al. (2011). Transcrip-
tion factor AP1 potentiates chromatin accessibility and glucocorticoid recep-
tor binding. Mol. Cell 43, 145–155.
Bookout, A.L., Jeong, Y., Downes, M., Yu, R.T., Evans, R.M., and Mangels-
dorf, D.J. (2006). Anatomical profiling of nuclear receptor expression reveals
a hierarchical transcriptional network. Cell 126, 789–799.
Bouillon, R., Carmeliet, G., Verlinden, L., van Etten, E., Verstuyf, A., Luderer,
H.F., Lieben, L., Mathieu, C., and Demay, M. (2008). Vitamin D and human
health: lessons from vitamin D receptor null mice. Endocr. Rev. 29, 726–776.
Bouwens, L., De Bleser, P., Vanderkerken, K., Geerts, B., andWisse, E. (1992).
Liver cell heterogeneity: functions of non-parenchymal cells. Enzyme 46,
155–168.
Breitkopf, K., Godoy, P., Ciuclan, L., Singer, M.V., and Dooley, S. (2006). TGF-
beta/Smad signaling in the injured liver. Z. Gastroenterol. 44, 57–66.
Chawla, A., Repa, J.J., Evans, R.M., and Mangelsdorf, D.J. (2001). Nuclear
receptors and lipid physiology: opening the X-files. Science 294, 1866–1870.
Cohen-Naftaly, M., and Friedman, S.L. (2011). Current status of novel antifi-
brotic therapies in patients with chronic liver disease. Therap. Adv. Gastroen-
terol. 4, 391–417.
Ding, N., Zhou, H., Esteve, P.O., Chin, H.G., Kim, S., Xu, X., Joseph, S.M.,
Friez, M.J., Schwartz, C.E., Pradhan, S., and Boyer, T.G. (2008). Mediator links
epigenetic silencing of neuronal gene expression with x-linked mental retarda-
tion. Mol. Cell 31, 347–359.
Feng, X.H., and Derynck, R. (2005). Specificity and versatility in tgf-beta
signaling through Smads. Annu. Rev. Cell Dev. Biol. 21, 659–693.
Friedman, S.L. (1993). Seminars in medicine of the Beth Israel Hospital,
Boston. The cellular basis of hepatic fibrosis. Mechanisms and treatment
strategies. N. Engl. J. Med. 328, 1828–1835.
Friedman, S.L. (1999). Evaluation of fibrosis and hepatitis C. Am. J. Med.
107(6B), 27S–30S.
Friedman, S.L. (2003). Liver fibrosis — from bench to bedside. J. Hepatol.
38(Suppl 1), S38–S53.
Friedman, S.L. (2008). Hepatic stellate cells: protean, multifunctional, and
enigmatic cells of the liver. Physiol. Rev. 88, 125–172.
Friedman, S.L., and Bansal, M.B. (2006). Reversal of hepatic fibrosis — fact or
fantasy? Hepatology 43(2, Suppl 1), S82–S88.
Friedman, S.L., Roll, F.J., Boyles, J., and Bissell, D.M. (1985). Hepatic lipo-
cytes: the principal collagen-producing cells of normal rat liver. Proc. Natl.
Acad. Sci. USA 82, 8681–8685.
Gascon-Barre´, M., Demers, C., Mirshahi, A., Ne´ron, S., Zalzal, S., and Nanci,
A. (2003). The normal liver harbors the vitamin D nuclear receptor in nonparen-
chymal and biliary epithelial cells. Hepatology 37, 1034–1042.
Geerts, A. (2001). History, heterogeneity, developmental biology, and func-
tions of quiescent hepatic stellate cells. Semin. Liver Dis. 21, 311–335.
Glass, C.K., and Saijo, K. (2010). Nuclear receptor transrepression pathways
that regulate inflammation in macrophages and T cells. Nat. Rev. Immunol.
10, 365–376.
Goltzman, D., Miao, D., Panda, D.K., and Hendy, G.N. (2004). Effects of
calcium and of the Vitamin D system on skeletal and calcium homeostasis:
lessons from genetic models. J. Steroid Biochem. Mol. Biol. 89-90, 485–489.
Griffin, M.D., Lutz, W., Phan, V.A., Bachman, L.A., McKean, D.J., and Kumar,
R. (2001). Dendritic cell modulation by 1alpha,25 dihydroxyvitamin D3 and its
analogs: a vitamin D receptor-dependent pathway that promotes a persistent
state of immaturity in vitro and in vivo. Proc. Natl. Acad. Sci. USA 98, 6800–
6805.
Han, S., Li, T., Ellis, E., Strom, S., and Chiang, J.Y. (2010). A novel bile acid-
activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol.
24, 1151–1164.
Han, Y.P. (2006). Matrix metalloproteinases, the pros and cons, in liver fibrosis.
J. Gastroenterol. Hepatol. 21(Suppl 3), S88–S91.
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y.C., Laslo, P., Cheng, J.X.,
Murre, C., Singh, H., and Glass, C.K. (2010). Simple combinations of lineage-
determining transcription factors prime cis-regulatory elements required for
macrophage and B cell identities. Mol. Cell 38, 576–589.
Hendriks, H.F., Verhoofstad, W.A., Brouwer, A., de Leeuw, A.M., and Knook,
D.L. (1985). Perisinusoidal fat-storing cells are the main vitamin A storage sites
in rat liver. Exp. Cell Res. 160, 138–149.
Hernandez-Gea, V., and Friedman, S.L. (2011). Pathogenesis of liver fibrosis.
Annu. Rev. Pathol. 6, 425–456.
Hua, S., Kittler, R., and White, K.P. (2009). Genomic antagonism between
retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259–1271.
Inagaki, Y., and Okazaki, I. (2007). Emerging insights into Transforming growth
factor beta Smad signal in hepatic fibrogenesis. Gut 56, 284–292.
Janssens, W., Mathieu, C., Boonen, S., and Decramer, M. (2011). Vitamin D
deficiency and chronic obstructive pulmonary disease: a vicious circle. Vitam.
Horm. 86, 379–399.
Kagan, H.M., and Li, W. (2003). Lysyl oxidase: properties, specificity, and bio-
logical roles inside and outside of the cell. J. Cell. Biochem. 88, 660–672.
Kim, W.R., Brown, R.S., Jr., Terrault, N.A., and El-Serag, H. (2002). Burden of
liver disease in the United States: summary of a workshop. Hepatology 36,
227–242.
Knook, D.L., Seffelaar, A.M., and de Leeuw, A.M. (1982). Fat-storing cells of
the rat liver. Their isolation and purification. Exp. Cell Res. 139, 468–471.
Lee, U.E., and Friedman, S.L. (2011). Mechanisms of hepatic fibrogenesis.
Best Pract. Res. Clin. Gastroenterol. 25, 195–206.
Li, M.O., and Flavell, R.A. (2008). TGF-beta: a master of all T cell trades. Cell
134, 392–404.
Li, Y.C., Pirro, A.E., Amling, M., Delling, G., Baron, R., Bronson, R., and Demay,
M.B. (1997). Targeted ablation of the vitamin D receptor: an animal model of
vitamin D-dependent rickets type II with alopecia. Proc. Natl. Acad. Sci.
USA 94, 9831–9835.
Lim, L.Y., and Chalasani, N. (2012). Vitamin d deficiency in patients with
chronic liver disease and cirrhosis. Curr. Gastroenterol. Rep. 14, 67–73.
Makishima, M., Lu, T.T., Xie, W., Whitfield, G.K., Domoto, H., Evans, R.M.,
Haussler, M.R., and Mangelsdorf, D.J. (2002). Vitamin D receptor as an intes-
tinal bile acid sensor. Science 296, 1313–1316.
Massague´, J. (2008). TGFbeta in Cancer. Cell 134, 215–230.
Massague´, J., Seoane, J., and Wotton, D. (2005). Smad transcription factors.
Genes Dev. 19, 2783–2810.
Munger, K.L., Levin, L.I., Hollis, B.W., Howard, N.S., and Ascherio, A. (2006).
Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296,
2832–2838.
Nagpal, S., Na, S., and Rathnachalam, R. (2005). Noncalcemic actions of
vitamin D receptor ligands. Endocr. Rev. 26, 662–687.Patsenker, E., and Stickel, F. (2011). Role of integrins in fibrosing liver
diseases. Am. J. Physiol. Gastrointest. Liver Physiol. 301, G425–G434.
Petta, S., Camma`, C., Scazzone, C., Tripodo, C., Di Marco, V., Bono, A.,
Cabibi, D., Licata, G., Porcasi, R., Marchesini, G., and Craxı´, A. (2010). Low
vitamin D serum level is related to severe fibrosis and low responsiveness to
interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 51,
1158–1167.
Ramagopalan, S.V., Dyment, D.A., Cader, M.Z., Morrison, K.M., Disanto, G.,
Morahan, J.M., Berlanga-Taylor, A.J., Handel, A., De Luca, G.C., Sadovnick,
A.D., et al. (2011). Rare variants in the CYP27B1 gene are associated with mul-
tiple sclerosis. Ann. Neurol. 70, 881–886.
Reynaert, H., Thompson, M.G., Thomas, T., and Geerts, A. (2002). Hepatic
stellate cells: role in microcirculation and pathophysiology of portal hyperten-
sion. Gut 50, 571–581.
Rosenbloom, J., Castro, S.V., and Jimenez, S.A. (2010). Narrative review:
fibrotic diseases: cellular and molecular mechanisms and novel therapies.
Ann. Intern. Med. 152, 159–166.
Seki, E., DeMinicis, S., Osterreicher, C.H., Kluwe, J., Osawa, Y., Brenner, D.A.,
and Schwabe, R.F. (2007). TLR4 enhances TGF-beta signaling and hepatic
fibrosis. Nat. Med. 13, 1324–1332.
Seki, E., and Schnabl, B. (2012). Role of innate immunity and the microbiota in
liver fibrosis: crosstalk between the liver and gut. J. Physiol. 590, 447–458.
Siegmund, S.V., Dooley, S., and Brenner, D.A. (2005). Molecular mechanisms
of alcohol-induced hepatic fibrosis. Dig. Dis. 23, 264–274.
Tanaka, A., Nezu, S., Uegaki, S., Kikuchi, K., Shibuya, A., Miyakawa, H., Taka-
hashi, S., Bianchi, I., Zermiani, P., Podda, M., et al. (2009). Vitamin D receptor
polymorphisms are associated with increased susceptibility to primary biliary
cirrhosis in Japanese and Italian populations. J. Hepatol. 50, 1202–1209.
Terrier, B., Carrat, F., Geri, G., Pol, S., Piroth, L., Halfon, P., Poynard, T., Sou-
berbielle, J.C., and Cacoub, P. (2011). Low 25-OH vitamin D serum levels
correlate with severe fibrosis in HIV-HCV co-infected patients with chronic
hepatitis. J. Hepatol. 55, 756–761.
Trompouki, E., Bowman, T.V., Lawton, L.N., Fan, Z.P., Wu, D.C., DiBiase, A.,
Martin, C.S., Cech, J.N., Sessa, A.K., Leblanc, J.L., et al. (2011). Lineage
regulators direct BMP and Wnt pathways to cell-specific programs during
differentiation and regeneration. Cell 147, 577–589.
Tsukada, S., Parsons, C.J., and Rippe, R.A. (2006). Mechanisms of liver
fibrosis. Clin. Chim. Acta 364, 33–60.
Vadasz, Z., Kessler, O., Akiri, G., Gengrinovitch, S., Kagan, H.M., Baruch, Y.,
Izhak, O.B., and Neufeld, G. (2005). Abnormal deposition of collagen around
hepatocytes in Wilson’s disease is associated with hepatocyte specific
expression of lysyl oxidase and lysyl oxidase like protein-2. J. Hepatol. 43,
499–507.
von Essen, M.R., Kongsbak, M., Schjerling, P., Olgaard, K., Odum, N., and
Geisler, C. (2010). Vitamin D controls T cell antigen receptor signaling and acti-
vation of human T cells. Nat. Immunol. 11, 344–349.
Williams, R. (2006). Global challenges in liver disease. Hepatology 44,
521–526.
Wynn, T.A. (2008). Cellular and molecular mechanisms of fibrosis. J. Pathol.
214, 199–210.
Xu, L., Hui, A.Y., Albanis, E., Arthur, M.J., O’Byrne, S.M., Blaner, W.S., Mu-
kherjee, P., Friedman, S.L., and Eng, F.J. (2005). Human hepatic stellate cell
lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54,
142–151.
Yoshiji, H., Kuriyama, S., Yoshii, J., Ikenaka, Y., Noguchi, R., Nakatani, T.,
Tsujinoue, H., Yanase, K., Namisaki, T., Imazu, H., and Fukui, H. (2002). Tissue
inhibitor of metalloproteinases-1 attenuates spontaneous liver fibrosis resolu-
tion in the transgenic mouse. Hepatology 36, 850–860.Cell 153, 601–613, April 25, 2013 ª2013 Elsevier Inc. 613
